Latest Breaking News On - புற்றுநோயியல் ஆராய்ச்சி - Page 1 : comparemela.com

Tubulis Establishes Scientific Advisory Board with Leading ADC Drug Development and Oncology Experts

Omaha's The Lund Company adds associate to brokerage division

Dr B Borooah Cancer Institute launches its first official journal

Xtalks Announces Its Life Science Webinar Calendar for August 2021

Solid second quarter for the biotech industry - BB Biotech raised its allocation to promising small and mid caps

Nachricht vom 23.07.2021 | 07:00 Solid second quarter for the biotech industry - BB Biotech raised its allocation to promising small and mid caps DGAP-News: BB BIOTECH AG / Key word(s): Half Year Report/Interim Report 23.07.2021 / 07:00 Media release of July 23, 2021 Interim report of BB Biotech AG as at June 30, 2021 Solid second quarter for the biotech industry - BB Biotech raised its allocation to promising small and mid caps Inflation moved higher during the second quarter as the economic recovery gathered steam, triggering temporary outflows of investor capital from growth sectors. Central banks signaled that the rise in inflation would be short-lived, after which capital began to flow back into tech and healthcare stocks. BB Biotech shares returned 5.8% in CHF and 6.1% in EUR in the second quarter of 2021. Their total return for the first half of 2021 including the dividend payout was 22.2% in CHF and 21.3% in EUR. BB Biotech took profits in Alexion, Biogen, Mode